Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Hear the latest updates in thoracic oncology from leading experts at the British Thoracic Oncology Group (BTOG) 2023 Annual Conference.
Visit BTOG.org to find out more and to register.
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
Hear the latest updates in thoracic oncology from leading experts at the British Thoracic Oncology Group (BTOG) 2023 Annual Conference.
Visit BTOG.org to find out more and to register.
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.